June 2022 - Page 3 of 3

TuesdayJun 14, 2022 9:00 am

Aditxt Inc.’s (NASDAQ: ADTX) AditxtScore(TM) Platform Provides Consumers and Physicians with Data Needed to Make Informed Health Decisions on COVID-19

Aditxt is a biotech innovation company developing and commercializing technologies focused on monitoring and reprogramming the immune system.The company’s AditxtScore(TM) for COVID-19 generates an AditxtScore(TM), which offers a detailed profile of a person’s immune response for SARS-CoV-2, allowing consumers and their physicians to understand, manage, and monitor their level of immune response to the virus, thus allowing them to make informed health decisionsAditxt’s platform is initially focusing on SARS-CoV-2, the virus that causes COVID-19, in recognition of the importance of immune monitoring and profiling in determining the course of action related to the virus. Though the COVID-19 pandemic is now…

MondayJun 13, 2022 9:45 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) and the Budding Alternative Nicotine Market

The nicotine pouch market is projected to reach $21.84 billion in 2027, up from $2.33 billion in 2020, representing a CAGR of 30.7%The smokeless tobacco products sector is expected to post a CAGR of 7.2% over the forecast period (2018-2025)Lexaria, through its patented DehydraTECH technology, is tapping into this important alternative nicotine sector Its management is confident that its research and technology development investment will pay off and provide greater consumer satisfaction. In 2019, it was estimated that at least 1.1 billion people globally smoked cigarettes regularly. 780 million, representing 71% of the global smoking population, noted that they wanted to…

FridayJun 10, 2022 9:00 am

New Spike in COVID Infections, 1M+ Death Toll, Underscore Potential Value of Aditxt Inc.’s (NASDAQ: ADTX) Immune Monitoring Technologies

Biotech innovation company Aditxt, Inc. is a Richmond, VA based company focused on developing and commercializing technologies to monitor and reprogram the immune system with the ultimate goal of improving patient outcomes for a variety of conditions ranging from seasonal allergies to organ transplant rejectionAditxt’s first commercial product, AditxtScore(TM), helps patients obtain data relating to COVID-19 infection and vulnerabilityWhile immunization rates and the seasonal reduction of COVID infections have spurred optimism about enjoying normal public activities, a recent spike in COVID infections has led national health officials to again warn Americans to not become complacent about the pandemicHealth officials also…

FridayJun 03, 2022 9:00 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Mines Potential of Helping Medicines Do What they Do, But Better

Lexaria Bioscience is a global innovator in drug delivery platforms, developing a technology designed to improve the performance of other medicinal products by making them more rapidly and effectively usable by patients’ bodiesLexaria’s patented DehydraTECH technology has been studied in combination with a number of other products, including but not limited to, cannabidiol (“CBD”), oral nicotine, antivirals, NSAIDs, and erectile dysfunction therapiesThe company is pursuing FDA approval under the Investigational New Drug (“IND”) process to clinically test its DehydraTECH-CBD for the treatment of high blood pressureA driving focus of the company’s R&D has been to improve the speed of onset,…

Spotlighting undiscovered companies with enormous upside potential.

Contact us: (310) 299-1717

Month: June 2022

Aditxt Inc.’s (NASDAQ: ADTX) AditxtScore(TM) Platform Provides Consumers and Physicians with Data Needed to Make Informed Health Decisions on COVID-19

Lexaria Bioscience Corp. (NASDAQ: LEXX) and the Budding Alternative Nicotine Market

New Spike in COVID Infections, 1M+ Death Toll, Underscore Potential Value of Aditxt Inc.’s (NASDAQ: ADTX) Immune Monitoring Technologies

Lexaria Bioscience Corp. (NASDAQ: LEXX) Mines Potential of Helping Medicines Do What they Do, But Better

TinyGems

Quote / Research

Site Search